ensifentrine (RPL554) - Verona Pharma
Ensifentrine: "Significant and clinically meaningful improvements in lung function at Week 12"; Chronic obstructive pulmonary disease (Verona Pharma) - Aug 18, 2022 - ENHANCE-2 Phase 3 Top-Line Data and Q2 Results Conference Call 
P3 data: top line Chronic Obstructive Pulmonary Disease • Immunology
https://ether-assets.ams3.cdn.digitaloceanspaces.com/verona-pharma/VRNA-ENH2-data-call-Slides_final.pdf
 
Aug 18, 2022
 
 
72bb9e88-fd9b-45a7-928d-0e5689dc6022.png

91c9cd2e-5793-462a-bd13-fc955d2724dc.png